Rituximab biosimilar (Nanjing Yoko Biomedical)

利妥昔单抗生物类似药（南京优科生物）

Report date: 2024/04/02 14:05:19

Base Information

Drug NameRituximab biosimilar (Nanjing Yoko Biomedical)
Drug Alias Name重组抗CD20人鼠嵌合单克隆抗体（嘉和生物）GB-241
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmHematologic NeoplasmsLymphoma, T-Cell +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGenor Biopharma Co LtdNanjing Yoko Biomedical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteThe University Of Texas MD Anderson Cancer CenterGenor Biopharma Co Ltd +[5] 
Inactive CompaniesRutgers University
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmHematologic NeoplasmsLymphoma, Follicular +[10] 
Inactive IndicationsLymphoma, T-CellLymphoma, Mantle-CellLymphoma, B-Cell, Marginal Zone +[7] 

Other Information

ATC CodeL01XC02
Related LinksN/A